查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1957514

2026年全球非病毒药物递送系统市场报告

Non-Viral Drug Delivery Systems Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，非病毒药物递送系统的市场规模迅速扩张。预计该市场规模将从2025年的98.4亿美元成长到2026年的112.6亿美元，复合年增长率（CAGR）为14.4%。成长要素包括：目前对病毒递送方式的依赖、对非病毒技术的认知度较低、新兴生物製药的开发、药物递送法规结构尚不完善，以及奈米颗粒相关学术研究尚处于起步阶段。

预计未来几年非病毒药物递送系统的市场规模将快速成长，到2030年将达到190.7亿美元，复合年增长率（CAGR）为14.1%。预测期内的成长预计将受到以下因素的推动：聚合物载体技术的进步、RNA和DNA疗法的发展、个人化医疗投资的增加、合约研发生产机构（CDMO）的扩张以及製药公司与学术机构之间合作的加强。预测期内的关键趋势包括：标靶治疗中非病毒递送平台的广泛应用、奈米颗粒和脂质体载体的日益普及、对降低免疫反应和提高安全性的重视、个人化医疗和标靶治疗的发展、CDMO的扩张以及与学术研究机构合作的加强。

预计未来几年，对个人化医疗日益增长的需求将推动非病毒药物递送系统市场的成长。个人化医疗是一种根据个人基因谱、生活方式和环境因素量身订做治疗方案的医疗方法。由于个人化医疗能够识别每位患者的疾病根源，从而实现更有效的治疗，因此其需求不断增长。非病毒药物递送系统在个人化医疗中发挥着辅助作用，它能够安全、精准地将药物和遗传物质递送至目标细胞，从而最大限度地降低风险并提高治疗的准确性。例如，根据美国非营利组织「个人化医疗联盟」（Coalition for Personalized Medicine）统计，截至2024年2月，美国食品药物管理局（FDA）在2023年核准了16种针对罕见疾病患者的新型个人化治疗方法，高于2022年的6种。因此，对个人化医疗不断增长的需求正在推动非病毒药物递送系统市场的成长。

在非病毒药物递送系统市场中，主要企业正致力于开发先进技术，例如预先优化离子化脂质混合物系统，以简化基于RNA的疗法的开发和递送。预先优化离子化脂质混合物系统是一种製剂技术，旨在将RNA分子高效封装在脂质奈米颗粒内，从而确保基因治疗应用中更高的稳定性、有效载荷保护和靶向递送能力。例如，2024年9月，美国生物技术公司Cytiva宣布推出一款用于RNA递送的脂质奈米颗粒（LNP）试剂盒，该试剂盒与其NanoAssemblr Ignite和Ignite+平台相容。本系统采用即用型离子化脂质混合物，可快速筛检RNA酬载并进行有效的递送检验，尤其适用于感染疾病疫苗的开发。它可与自动化微流体平台无缝集成，支援使用GMP级组件进行可扩展生产，并提供通讯协定和概念验证数据，以帮助用户从早期发现到临床评估。

目录

第一章：执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球非病毒药物递送系统市场：吸引力评分及分析
  • 成长潜力分析、竞争评估、策略适宜性评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 清单：主要原料、资源和供应商
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章：全球市场趋势与策略

  • 关键科技与未来趋势
    • 生物技术、基因组学和精准医疗
    • 工业4.0和智慧製造
    • 数位化、云端运算、巨量资料、网路安全
    • 人工智慧（AI）和自主人工智慧
    • 物联网、智慧基础设施、互联生态系统
  • 主要趋势
    • 标靶治疗中非病毒递送平台的应用日益增多
    • 奈米颗粒和脂质体载体的应用日益增多
    • 重点在于降低免疫反应、提高安全性
    • 个人化医疗和标靶治疗的发展
    • 扩大CDMO与学术研究之间的合作。

第五章 终端用户产业市场分析

  • 製药公司
  • 生技公司
  • 学术研究机构
  • 合约研发生产组织（CDMO）
  • 医院和诊所

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及 COVID-19 疫情对市场的影响。

第七章：全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球非病毒药物递送系统市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 全球非病毒药物递送系统市场规模、比较及成长率分析
  • 全球非病毒药物递送系统市场表现：规模与成长，2020-2025年
  • 全球非病毒药物递送系统市场预测：规模与成长，2025-2030年，2035年预测

第八章：全球市场总规模（TAM）

第九章 市场细分

  • 依分子类型
  • 生物製药，小分子药物
  • 依所提供的生物製药类型
  • 核糖核酸（RNA）、去氧核糖核酸（DNA）、蛋白质或胜肽、抗体
  • 最终用户
  • 製药和生物技术公司、学术研究机构、合约开发和生产组织（CDMO）、医院和诊所
  • 按类型细分：生物製药
  • 肽类、蛋白质、单株抗体、基于RNA的疗法、基于DNA的治疗方法
  • 按类型细分：小分子化合物
  • 化疗药物、抗发炎药物、抗病毒药物、抗生素、荷尔蒙

第十章 区域与国别分析

  • 全球非病毒药物递送系统市场：按地区划分，历史资料及预测（2020-2025年、2025-2030年预测、2035年预测）
  • 全球非病毒药物递送系统市场：依国家划分，历史资料及预测，2020-2025年、2025-2030年预测、2035年预测

第十一章 亚太市场

第十二章：中国市场

第十三章：印度市场

第十四章：日本市场

第十五章：澳洲市场

第十六章：印尼市场

第十七章：韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第20章 西欧市场

第21章英国市场

第22章：德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章：东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第三十章：加拿大市场

第31章：南美市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第三十五章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 非病毒药物递送系统市场：竞争格局与市场份额，2024 年
  • 非病毒药物递送系统市场：公司估值矩阵
  • 非病毒药物递送系统市场：公司概况
    • Evonik Industries AG
    • Cytiva
    • Arcturus Therapeutics Holdings Inc.
    • CureVac NV
    • PolyPid Ltd

第37章 其他大型企业和创新企业

  • Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd

第38章：全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年非病毒药物递送系统市场：提供新机会的国家
  • 2030年非病毒药物递送系统市场：充满新机会的细分市场
  • 2030年非病毒药物递送系统市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第41章附录

简介目录
Product Code: PH5MNVDD01_G26Q1

Non-viral drug delivery systems refer to approaches for administering therapeutic agents into the body without the use of viral vectors. These systems employ physical, chemical, or mechanical methods such as nanoparticles, liposomes, and polymer-based carriers to safely transport drugs to specific target sites. They are designed to minimize the risks associated with viral delivery, including immune responses and insertional mutagenesis. This strategy improves treatment effectiveness and enhances patient safety across a wide range of medical conditions.

The main types of molecules delivered through non-viral drug delivery systems include biologics and small molecules. Biologics are therapeutics derived from living sources and include proteins, peptides, monoclonal antibodies, and nucleic acid-based therapies such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). The biologic types delivered comprise RNA, DNA, proteins or peptides, and antibodies. The key end users include pharmaceutical and biotechnology companies, academic and research institutions, contract development and manufacturing organizations (CDMOs), as well as hospitals and clinics.

Tariffs have affected the non-viral drug delivery systems market by increasing the cost of imported materials such as specialized polymers, lipids, and nanoparticles. Segments including RNA-based therapeutics and liposome carriers are most impacted, particularly in regions like Asia-Pacific where manufacturing hubs such as China and India face import duties. This has led to higher production costs and adjustments in supply chains. Positively, tariffs are driving local production, innovation in alternative materials, and greater investment in domestic manufacturing capabilities.

The non-viral drug delivery systems market research report is one of a series of new reports from The Business Research Company that provides non-viral drug delivery systems market statistics, including non-viral drug delivery systems industry global market size, regional shares, competitors with a non-viral drug delivery systems market share, detailed non-viral drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral drug delivery systems industry. This non-viral drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-viral drug delivery systems market size has grown rapidly in recent years. It will grow from $9.84 billion in 2025 to $11.26 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to reliance on viral delivery methods, limited awareness of non-viral techniques, emerging biologics development, initial regulatory frameworks for drug delivery, early academic research focus on nanoparticles.

The non-viral drug delivery systems market size is expected to see rapid growth in the next few years. It will grow to $19.07 billion in 2030 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to advancements in polymer-based carriers, growth of rna and dna therapeutics, increasing investment in personalized medicine, expansion of contract development and manufacturing organizations (cdmos), rising collaborations between pharma and academic institutions. Major trends in the forecast period include rising adoption of non-viral delivery platforms for targeted therapies, increasing use of nanoparticles and liposome-based carriers, focus on reducing immune response and enhancing safety, growth in personalized medicine and targeted therapeutics, expansion of cdmos and academic research collaborations.

The rising demand for personalized medicines is anticipated to drive the growth of the non-viral drug delivery systems market in the coming years. Personalized medicine is a healthcare approach that customizes treatment based on an individual's genetic profile, lifestyle, and environmental factors. The demand for personalized medicine is increasing because it enables more effective therapies by addressing the specific underlying causes of disease in each patient. Non-viral drug delivery systems support personalized medicine by enabling the safe and precise delivery of drugs or genetic material to target cells, minimizing risks and improving treatment accuracy. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration approved 16 new personalized therapies for patients with rare diseases, up from 6 approvals in 2022. Therefore, the growing demand for personalized medicines is fueling the growth of the non-viral drug delivery systems market.

Major companies operating in the non-viral drug delivery systems market are concentrating on advanced technologies, such as pre-optimized ionizable lipid mix systems, to simplify the development and delivery of RNA-based therapeutics. A pre-optimized ionizable lipid mix system is a formulation technology designed to efficiently encapsulate RNA molecules within lipid nanoparticles, ensuring enhanced stability, protection of the payload, and targeted delivery for gene-based therapeutic applications. For example, in September 2024, Cytiva, a US-based biotechnology company, introduced an RNA delivery lipid nanoparticle (LNP) kit compatible with its NanoAssemblr Ignite and Ignite+ platforms. This system features a ready-to-use ionizable lipid mix that enables rapid screening of RNA payloads and effective delivery validation, particularly for infectious disease vaccine development. It integrates seamlessly with automated microfluidic platforms, supports scalable manufacturing using GMP-grade components, and provides protocols along with proof-of-concept data to support users from early discovery through clinical evaluation.

In September 2023, SOHM Inc., a US-based pharmaceutical company, acquired ABBIE from CGA 369 for $10 million. Through this acquisition, SOHM enhanced its capabilities in delivering large genetic payloads using integrase-based, non-viral technologies. ABBIE is being developed as an off-the-shelf gene-editing kit, with commercialization planned for 2024 and human trials expected by late 2025. CGA 369 is a US-based biotechnology company specializing in non-viral, integrase-based gene-editing and genetic payload delivery systems.

Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.

North America was the largest region in the non-viral drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-viral drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-viral drug delivery systems market consists of sales of exosomes, cell-penetrating peptides, and nanocrystals. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Viral Drug Delivery Systems Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses non-viral drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-viral drug delivery systems ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-viral drug delivery systems market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type Of Molecule Delivered: Biologics; Small Molecules
  • 2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA); Deoxyribonucleic Acid (DNA); Proteins or Peptides; Antibodies
  • 3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Contract Development And Manufacturing Organizations (CDMOs); Hospitals And Clinics
  • Subsegments:
  • 1) By Biologics: Peptides; Proteins; Monoclonal Antibodies; RNA-based Therapeutics; DNA-based Therapies
  • 2) By Small Molecules: Chemotherapeutics; Anti-inflammatories; Antivirals; Antibiotics; Hormonal Drugs
  • Companies Mentioned: Evonik Industries AG; Cytiva; Arcturus Therapeutics Holdings Inc.; CureVac N.V.; PolyPid Ltd; Ethris GmbH; Entos Pharmaceuticals Inc.; Liquidia Technologies Inc.; ReCode Therapeutics Inc.; Enable Injections Inc.; GenEdit Inc.; N4 Pharma Plc; Hopewell Therapeutics Inc.; Tiba Biotech LLC; Vesigen Therapeutics Inc.; Carmine Therapeutics Inc.; Evox Therapeutics Ltd; InnoCore Pharmaceuticals BV; Nanomerics Ltd; DelSiTech Ltd; Curapath Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Non-Viral Drug Delivery Systems Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Non-Viral Drug Delivery Systems Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Non-Viral Drug Delivery Systems Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Non-Viral Drug Delivery Systems Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Industry 4.0 & Intelligent Manufacturing
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Rising Adoption Of Non-Viral Delivery Platforms For Targeted Therapies
    • 4.2.2 Increasing Use Of Nanoparticles And Liposome-Based Carriers
    • 4.2.3 Focus On Reducing Immune Response And Enhancing Safety
    • 4.2.4 Growth In Personalized Medicine And Targeted Therapeutics
    • 4.2.5 Expansion Of Cdmos And Academic Research Collaborations

5. Non-Viral Drug Delivery Systems Market Analysis Of End Use Industries

  • 5.1 Pharmaceutical Companies
  • 5.2 Biotechnology Companies
  • 5.3 Academic And Research Institutes
  • 5.4 Contract Development And Manufacturing Organizations (Cdmos)
  • 5.5 Hospitals And Clinics

6. Non-Viral Drug Delivery Systems Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Non-Viral Drug Delivery Systems Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Non-Viral Drug Delivery Systems PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Non-Viral Drug Delivery Systems Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Non-Viral Drug Delivery Systems Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Non-Viral Drug Delivery Systems Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Non-Viral Drug Delivery Systems Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Non-Viral Drug Delivery Systems Market Segmentation

  • 9.1. Global Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Biologics, Small Molecules
  • 9.2. Global Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies
  • 9.3. Global Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics
  • 9.4. Global Non-Viral Drug Delivery Systems Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
  • 9.5. Global Non-Viral Drug Delivery Systems Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs

10. Non-Viral Drug Delivery Systems Market Regional And Country Analysis

  • 10.1. Global Non-Viral Drug Delivery Systems Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Non-Viral Drug Delivery Systems Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Non-Viral Drug Delivery Systems Market

  • 11.1. Asia-Pacific Non-Viral Drug Delivery Systems Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Non-Viral Drug Delivery Systems Market

  • 12.1. China Non-Viral Drug Delivery Systems Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Non-Viral Drug Delivery Systems Market

  • 13.1. India Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Non-Viral Drug Delivery Systems Market

  • 14.1. Japan Non-Viral Drug Delivery Systems Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Non-Viral Drug Delivery Systems Market

  • 15.1. Australia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Non-Viral Drug Delivery Systems Market

  • 16.1. Indonesia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Non-Viral Drug Delivery Systems Market

  • 17.1. South Korea Non-Viral Drug Delivery Systems Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Non-Viral Drug Delivery Systems Market

  • 18.1. Taiwan Non-Viral Drug Delivery Systems Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Non-Viral Drug Delivery Systems Market

  • 19.1. South East Asia Non-Viral Drug Delivery Systems Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Non-Viral Drug Delivery Systems Market

  • 20.1. Western Europe Non-Viral Drug Delivery Systems Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Non-Viral Drug Delivery Systems Market

  • 21.1. UK Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Non-Viral Drug Delivery Systems Market

  • 22.1. Germany Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Non-Viral Drug Delivery Systems Market

  • 23.1. France Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Non-Viral Drug Delivery Systems Market

  • 24.1. Italy Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Non-Viral Drug Delivery Systems Market

  • 25.1. Spain Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Non-Viral Drug Delivery Systems Market

  • 26.1. Eastern Europe Non-Viral Drug Delivery Systems Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Non-Viral Drug Delivery Systems Market

  • 27.1. Russia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Non-Viral Drug Delivery Systems Market

  • 28.1. North America Non-Viral Drug Delivery Systems Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Non-Viral Drug Delivery Systems Market

  • 29.1. USA Non-Viral Drug Delivery Systems Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Non-Viral Drug Delivery Systems Market

  • 30.1. Canada Non-Viral Drug Delivery Systems Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Non-Viral Drug Delivery Systems Market

  • 31.1. South America Non-Viral Drug Delivery Systems Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Non-Viral Drug Delivery Systems Market

  • 32.1. Brazil Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Non-Viral Drug Delivery Systems Market

  • 33.1. Middle East Non-Viral Drug Delivery Systems Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Non-Viral Drug Delivery Systems Market

  • 34.1. Africa Non-Viral Drug Delivery Systems Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Non-Viral Drug Delivery Systems Market Regulatory and Investment Landscape

36. Non-Viral Drug Delivery Systems Market Competitive Landscape And Company Profiles

  • 36.1. Non-Viral Drug Delivery Systems Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Non-Viral Drug Delivery Systems Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Non-Viral Drug Delivery Systems Market Company Profiles
    • 36.3.1. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Cytiva Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Arcturus Therapeutics Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. CureVac N.V. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. PolyPid Ltd Overview, Products and Services, Strategy and Financial Analysis

37. Non-Viral Drug Delivery Systems Market Other Major And Innovative Companies

  • Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd

38. Global Non-Viral Drug Delivery Systems Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Non-Viral Drug Delivery Systems Market

40. Non-Viral Drug Delivery Systems Market High Potential Countries, Segments and Strategies

  • 40.1 Non-Viral Drug Delivery Systems Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Non-Viral Drug Delivery Systems Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Non-Viral Drug Delivery Systems Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer